「gui」の検索結果

Guides experiment state transitions: launching, pausing, resuming, ending, shipping variants, archiving, resetting, duplicating, and copying to another project. Covers preconditions, implications for variant assignment and analysis, and the decision framework for when to use each action. TRIGGER when: user asks to launch, pause, resume, end, ship, archive, reset, duplicate, or copy an experiment to another project. DO NOT TRIGGER when: user is creating an experiment (use creating-experiments), configuring rollout (use configuring-experiment-rollout), or setting up metrics (use configuring-experiment-analytics).

日本語の概要は準備中です。原文の説明を表示しています。

Guide for creating high-quality MCP (Model Context Protocol) servers that enable LLMs to interact with external services through well-designed tools. Use when building MCP servers to integrate external APIs or services, whether in Python (FastMCP) or Node/TypeScript (MCP SDK).

日本語の概要は準備中です。原文の説明を表示しています。

Guides agents through creating and safely sizing a Replay Vision scanner: choosing the scanner type (monitor/classifier/scorer/summarizer), shaping the RecordingsQuery that selects sessions, and — crucially — estimating observation volume and checking the org's monthly quota before creating, so a broad scanner doesn't exhaust the budget on its first scheduled sweep. TRIGGER when: user asks to create, set up, or configure a Replay Vision scanner, OR when you are about to call vision-scanners-create, OR when widening an existing scanner's query or sampling_rate via vision-scanners-update. DO NOT TRIGGER when: only reading scanners or observations, deleting a scanner, or running an existing scanner against a single session on demand (vision-scanners-scan-session).

日本語の概要は準備中です。原文の説明を表示しています。

Guides agents through the 3-step experiment creation flow: defining the hypothesis, configuring rollout, and setting up analytics. Delegates rollout decisions to configuring-experiment-rollout and metric setup to configuring-experiment-analytics. TRIGGER when: user asks to create a new experiment or A/B test, OR when you are about to call experiment-create. DO NOT TRIGGER when: user is updating an existing experiment, managing lifecycle, or only browsing experiments.

日本語の概要は準備中です。原文の説明を表示しています。

Guidance for distinctive, intentional visual design when building new UI or reshaping an existing one. Helps with aesthetic direction, typography, and making choices that don't read as templated defaults.

日本語の概要は準備中です。原文の説明を表示しています。

Guides a user from "I want to watch recordings but don't know which ones" to a short, high-signal list of sessions worth watching. Use when the user asks which sessions or replays to watch, wants help finding interesting / useful recordings, says they don't know where to start in session replay, or wants to watch sessions about a goal (signup, pricing, onboarding, checkout, a feature, rageclicks, errors, mobile, a specific person) without naming exact filters. Turns a vague intent into a focused RecordingsQuery via `query-session-recordings-list`, then deep-links the best few and hands off to `investigating-replay`. Do NOT use when the user already has a recording/session ID (use investigating-replay) or wants the replay for a known error issue (use finding-replay-for-issue).

日本語の概要は準備中です。原文の説明を表示しています。

Guides exploration of $autocapture events captured by posthog-js to understand user interactions, find CSS selectors (especially data-attr attributes), evaluate selector uniqueness, query matching clicks ad-hoc, and create actions. Use when the user asks about autocapture data, wants to find what users are clicking, needs to build actions from click events, asks about elements_chain, wants to build a trend or funnel filtered by clicks or other autocapture interactions, asks which properties autocapture sends, or asks how to filter $autocapture events. Only applies to projects using posthog-js autocapture.

日本語の概要は準備中です。原文の説明を表示しています。

Guide users through a structured workflow for co-authoring documentation. Use when user wants to write documentation, proposals, technical specs, decision docs, or similar structured content. This workflow helps users efficiently transfer context, refine content through iteration, and verify the doc works for readers. Trigger when user mentions writing docs, creating proposals, drafting specs, or similar documentation tasks.

日本語の概要は準備中です。原文の説明を表示しています。

Write, review, and improve blog posts for the Sentry engineering blog following Sentry's specific writing standards, voice, and quality bar. Use this skill whenever someone asks to write a blog post, draft a technical article, review blog content, improve a draft, write a product announcement, create an engineering deep-dive, or produce any written content destined for the Sentry blog or developer audience. Also trigger when the user mentions "blog post," "blog draft," "write-up," "announcement post," "engineering post," "deep dive," "postmortem," or asks for help with technical writing for Sentry. Even if the user just says "help me write about [feature/topic]" — if it sounds like it could become a Sentry blog post, use this skill.

日本語の概要は準備中です。原文の説明を表示しています。

Strategic clinical trial design feasibility assessment. Analyzes 6 dimensions (endpoint, population, comparator, effect size, duration, regulatory pathway) using precedent trials and FDA guidance. Produces enrollment projections, endpoint recommendations, and approval-pathway analysis. Use for trial-protocol design, power/sample-size estimation, comparator selection, and FDA submission strategy. Driven by precedent-based reasoning rather than first-principles math.

日本語の概要は準備中です。原文の説明を表示しています。

Synthesize scientific evidence into a claim-to-source matrix, distinguish primary evidence from interpretation, assess disagreement and study limitations, and produce a calibrated research summary.

日本語の概要は準備中です。原文の説明を表示しています。

Calculates statistical power for high-dimensional genomics experiments (bulk RNA-seq, scRNA-seq, ATAC-seq, ChIP-seq, methylation, proteomics) under negative-binomial count models using RNASeqPower, PROPER, and simulation via powsimR, distinguishing per-gene from marginal (transcriptome-wide) power, the role of mean expression and dispersion, and the sequencing-depth-versus-replicate tradeoff. Covers simulation as the honest default for overdispersed counts, FDR-aware average power versus single-test power, observed/post-hoc power as an anti-pattern, and the winner's-curse / Type-S / Type-M consequences of underpowering. Use when planning replicate number for a sequencing experiment, deciding whether to add depth or samples, choosing closed-form versus simulation power, estimating power from pilot dispersions, or justifying replication in a grant. For clinical-trial power see clinical-biostatistics/power-and-sample-size; for the inverse sample-size question see experimental-design/sample-size.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.

日本語の概要は準備中です。原文の説明を表示しています。

Mendelian randomization (MR) causal inference — does an exposure, risk factor, or biomarker CAUSALLY affect a disease/outcome, using genetic variants as instrumental variables (IEU OpenGWAS / EpiGraphDB MR-EvE). Use this whenever the user asks if X causes Y, whether an observational association is actually causal or just correlation, if a biomarker/trait is a causal risk factor, wants to triangulate epidemiology against genetic evidence, or mentions Mendelian randomization, instrumental-variable analysis, two-sample MR, or genetic causal evidence — even if they never say "MR" (e.g. "is LDL cholesterol actually causal for heart disease?", "does BMI cause type 2 diabetes or just correlate?", "is CRP a causal driver of stroke?"). Covers trait-label resolution, MR effect direction/magnitude, instrument quality (MOE score), method agreement (IVW vs MR-Egger vs weighted median), bidirectional MR for reverse causation, and distinguishing causation from genetic correlation. Not for plain GWAS association lookups (use the GWAS skills) or fitting your own instruments from raw summary statistics.

日本語の概要は準備中です。原文の説明を表示しています。

Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.

日本語の概要は準備中です。原文の説明を表示しています。

Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.

日本語の概要は準備中です。原文の説明を表示しています。

Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.

日本語の概要は準備中です。原文の説明を表示しています。

Provides guidance for performing causal interventions on PyTorch models using pyvene's declarative intervention framework. Use when conducting causal tracing, activation patching, interchange intervention training, or testing causal hypotheses about model behavior.

日本語の概要は準備中です。原文の説明を表示しています。

Provides guidance for mechanistic interpretability research using TransformerLens to inspect and manipulate transformer internals via HookPoints and activation caching. Use when reverse-engineering model algorithms, studying attention patterns, or performing activation patching experiments.

日本語の概要は準備中です。原文の説明を表示しています。

Provides guidance for training and analyzing Sparse Autoencoders (SAEs) using SAELens to decompose neural network activations into interpretable features. Use when discovering interpretable features, analyzing superposition, or studying monosemantic representations in language models.

日本語の概要は準備中です。原文の説明を表示しています。

Expert guidance for Fully Sharded Data Parallel training with PyTorch FSDP - parameter sharding, mixed precision, CPU offloading, FSDP2

日本語の概要は準備中です。原文の説明を表示しています。

Provides guidance for interpreting and manipulating neural network internals using nnsight with optional NDIF remote execution. Use when needing to run interpretability experiments on massive models (70B+) without local GPU resources, or when working with any PyTorch architecture.

日本語の概要は準備中です。原文の説明を表示しています。